NO304186B1 - 1H-indol-3-glykosylamid og farmas°ytisk formulering - Google Patents

1H-indol-3-glykosylamid og farmas°ytisk formulering

Info

Publication number
NO304186B1
NO304186B1 NO951252A NO951252A NO304186B1 NO 304186 B1 NO304186 B1 NO 304186B1 NO 951252 A NO951252 A NO 951252A NO 951252 A NO951252 A NO 951252A NO 304186 B1 NO304186 B1 NO 304186B1
Authority
NO
Norway
Prior art keywords
indole
glycosylamide
pharmaceutical formulation
sub
glyoxylamides
Prior art date
Application number
NO951252A
Other languages
English (en)
Norwegian (no)
Other versions
NO951252D0 (no
NO951252L (no
Inventor
Nicholas James Bach
Robert Delane Dillard
Susan Elizabeth Draheim
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO951252D0 publication Critical patent/NO951252D0/no
Publication of NO951252L publication Critical patent/NO951252L/no
Publication of NO304186B1 publication Critical patent/NO304186B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
NO951252A 1994-04-01 1995-03-31 1H-indol-3-glykosylamid og farmas°ytisk formulering NO304186B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22191694A 1994-04-01 1994-04-01

Publications (3)

Publication Number Publication Date
NO951252D0 NO951252D0 (no) 1995-03-31
NO951252L NO951252L (no) 1995-10-02
NO304186B1 true NO304186B1 (no) 1998-11-09

Family

ID=22829963

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951252A NO304186B1 (no) 1994-04-01 1995-03-31 1H-indol-3-glykosylamid og farmas°ytisk formulering

Country Status (29)

Country Link
US (6) US5654326A (de)
EP (5) EP2341045A1 (de)
JP (1) JP3109974B2 (de)
KR (1) KR100368707B1 (de)
CN (1) CN1067054C (de)
AT (2) ATE220394T1 (de)
AU (1) AU688458B2 (de)
BR (1) BR9501404A (de)
CA (1) CA2146097C (de)
CO (1) CO4370099A1 (de)
CZ (1) CZ82295A3 (de)
DE (1) DE69527322T2 (de)
DK (2) DK0675110T3 (de)
ES (2) ES2377223T3 (de)
FI (1) FI114793B (de)
HU (1) HUT72048A (de)
IL (1) IL113210A (de)
MX (1) MX9501608A (de)
MY (1) MY112897A (de)
NO (1) NO304186B1 (de)
NZ (1) NZ270848A (de)
PE (1) PE18696A1 (de)
PL (1) PL180523B1 (de)
PT (1) PT675110E (de)
RU (1) RU2128169C1 (de)
SI (1) SI0675110T1 (de)
TW (1) TW383302B (de)
UA (1) UA47387C2 (de)
ZA (1) ZA952693B (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL180523B1 (pl) 1994-04-01 2001-02-28 Eli Lilly & Co Nowy zwiazek, pochodna 1H-indolo-3-glioksylamidu i srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
JPH08193074A (ja) * 1994-11-18 1996-07-30 Nippon Bayeragrochem Kk 除草性１−シクロプロピルテトラゾリノン類
KR100436812B1 (ko) * 1995-01-06 2004-08-31 도레이 가부시끼가이샤 벤젠축합헤테로환유도체및그유도체를유효성분으로함유하는의약조성물
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
US5919774A (en) * 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
AU6229298A (en) * 1997-02-20 1998-09-09 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
US5972988A (en) * 1997-03-26 1999-10-26 Eli Lilly And Company Method for treatment of chronic bronchitis using indole compounds
WO1998047507A1 (en) 1997-04-24 1998-10-29 Shionogi & Co., Ltd. Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
JP2001513555A (ja) * 1997-08-28 2001-09-04 イーライ・リリー・アンド・カンパニー 非リウマチ様関節炎の処置方法
EP1039911B1 (de) * 1997-10-27 2005-05-25 Eli Lilly And Company MORPHOLINO-N-ETHYL ESTER PRODROGEN VON INDOL sPLA 2 HEMMER
WO1999021545A1 (en) * 1997-10-27 1999-05-06 Eli Lilly And Company ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
CA2309135A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
WO1999025339A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
SK12752000A3 (sk) * 1998-02-25 2001-03-12 Genetics Institute, Inc. Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
DE69928500T2 (de) * 1998-03-03 2006-08-03 Eli Lilly And Co., Indianapolis Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium-[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetat
AU3054399A (en) 1998-03-31 1999-10-25 Shionogi & Co., Ltd. Pyrrolo(1,2-a)pyrazine sPLA2 inhibitor
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
CZ302588B6 (cs) * 1998-04-02 2011-07-27 Ziopharm Oncology, Inc. Použití N-substituovaného indol-3-glyoxylamidu pro výrobu léciva
US6407261B1 (en) 1998-04-17 2002-06-18 Eli Lilly And Company Process for preparing 4-hdyroxy indole, indazole and carbazole compounds
DZ2770A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
EP1071661A4 (de) * 1998-04-17 2001-08-22 Lilly Co Eli Verfahren zur herstellung von 4-hydroxyindol-, indazol- und carbazol-verbindungen
PL344571A1 (en) * 1998-05-01 2001-11-05 Lilly Co Eli Spla2
CA2330856A1 (en) * 1998-05-01 1999-11-11 Eli Lilly And Company Spla2 inhibitor compounds for treatment of disease
CN1302300A (zh) 1998-05-21 2001-07-04 盐野义制药株式会社 吡咯并[1,2－b]哒嗪sPLA2抑制剂
WO2000007590A1 (en) * 1998-08-03 2000-02-17 Eli Lilly And Company INDOLE sPLA2 INHIBITORS
EP1100493A4 (de) 1998-08-03 2001-10-24 Lilly Co Eli INHIBITOREN DER sPLA 2? DES INDOLTYPS
WO2000010568A1 (en) 1998-08-24 2000-03-02 Draheim Susan E Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase a¿2?
US6576654B1 (en) 1998-09-23 2003-06-10 Eli Lilly And Company Method for the treatment of cystic fibrosis
DZ2771A1 (fr) * 1998-10-09 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
CA2346334A1 (en) 1998-10-14 2000-04-20 Shionogi & Co., Ltd. Composition for treating or preventing ischemia reperfusion injury
US20030149000A1 (en) * 1998-11-10 2003-08-07 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds
AU1940800A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Combination therapy for the treatment of sepsis
EP1144305A4 (de) * 1998-12-22 2004-11-10 Lilly Co Eli NEUE sPLA 2 INHIBITOREN
ATE247119T1 (de) * 1998-12-22 2003-08-15 Lilly Co Eli Substituierte pyrroloindole
US6380397B1 (en) 1999-04-15 2002-04-30 Eli Lilly And Company Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6274578B1 (en) 1999-04-20 2001-08-14 Eli Lilly And Company sPLA2 inhibitor ester
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
CA2379208A1 (en) * 1999-07-19 2001-01-25 Eli Lilly & Company Spla2 inhibitors
JP4636521B2 (ja) 1999-07-19 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環系化合物
JP4636522B2 (ja) 1999-08-02 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環式化合物
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6831095B1 (en) 1999-09-20 2004-12-14 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
JP2003509491A (ja) * 1999-09-20 2003-03-11 イーライ・リリー・アンド・カンパニー 新規なｓＰＬＡ２インヒビター
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
US6756376B1 (en) 1999-11-15 2004-06-29 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
AU2252201A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
WO2001044184A1 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Synthesis of indole-containing spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
KR20030016214A (ko) * 2000-01-06 2003-02-26 일라이 릴리 앤드 캄파니 염증성 및 호흡기 질환의 치료를 위한 복합 치료법
WO2001049662A2 (en) * 2000-01-07 2001-07-12 Eli Lilly And Company Carbazole derivatives as inhibitors of spla2
US20030096854A1 (en) * 2002-06-12 2003-05-22 Ho-Shen Lin Substituted tricyclics
JP2003525901A (ja) * 2000-03-09 2003-09-02 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターによる腎臓機能障害の治療方法
BR0002188A (pt) * 2000-03-30 2001-11-13 Brasil Compressores Sa Processo de formação do pacote de lâminasmetálicas de estator de motor elétrico e pacotede lâminas metálicas
AU2001252922A1 (en) * 2000-04-19 2001-11-07 Eli Lilly And Company Azide cyclization-based synthesis and intermediates for spla2 inhibitors
AU2001267826A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for alzheimer's disease
ES2294003T3 (es) * 2000-06-29 2008-04-01 Anthera Pharmaceuticals, Inc. Remedios contra el cancer.
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
AU2001267825A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
WO2002012249A2 (en) * 2000-08-04 2002-02-14 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
JP2004520363A (ja) 2000-12-18 2004-07-08 イーライ・リリー・アンド・カンパニー 新規なｓＰＬＡ２インヒビター
TWI314457B (de) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
TWI323658B (en) 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
WO2007056184A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Azaindole compounds and use thereof as phospholipase-a2 inhibitors
AU2006311766A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having C4-acidic substituents and use thereof as phospholipase-A2 inhibitors
JP2009517341A (ja) * 2005-11-03 2009-04-30 イリプサ， インコーポレイテッド Ｃ４−アミド置換基を有するインドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
EP1960356A2 (de) 2005-11-03 2008-08-27 Ilypsa, Inc. Mehrwertige indolverbindungen und deren verwendung als phospholipase-a2-inhibitoren
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
CN104710365A (zh) * 2008-04-28 2015-06-17 旭化成制药株式会社 苯丙酸衍生物及其用途
US20100204249A1 (en) * 2009-01-08 2010-08-12 Colin Hislop Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN101838232B (zh) * 2009-07-07 2012-02-22 爱斯医药科技(南京)有限公司 Varespladib的制备方法
MA40998A (fr) * 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
CN108463221A (zh) * 2015-08-31 2018-08-28 迪亚库雷特公司 吲哚类化合物刺激免疫系统的用途
EP3448378B1 (de) * 2016-04-29 2024-04-17 Ophirex, Inc. Pla2 und hmg-coa-inhibitoren zur behandlung von pathologischen zuständen, die hämolyse, zerebrales ödem und akute nierenschädigung verursachen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
US2825743A (en) 1955-08-30 1958-03-04 Celanese Corp Catalytic hydrogenation of unsaturated aldehydes and ketones
US3242163A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3259622A (en) * 1962-09-07 1966-07-05 Merck & Co Inc 1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids
GB1089071A (en) 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
NL287416A (de) 1964-04-25
US3449363A (en) 1966-12-22 1969-06-10 American Cyanamid Co 3-substituted 4-trifluoromethyl indoles
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
US3691194A (en) * 1970-07-30 1972-09-12 Little Inc A 3-indole-glyoxamides
US3686213A (en) 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
US4012513A (en) * 1971-11-03 1977-03-15 Imperial Chemical Industries Limited Indole derivatives for providing analgesic and anti-inflammatory effects
US4397850A (en) 1981-10-07 1983-08-09 Sandoz, Inc. Isoxazolyl indolamines
US4552876A (en) * 1984-07-09 1985-11-12 Usv Pharmaceutical Corp. Bisbenzoxazines and pharmaceutical use
US4743609A (en) * 1985-02-12 1988-05-10 Banyu Pharmaceutical Co., Ltd. Indole derivatives having gastric and antisecretory and cytoprotective properties, and pharmaceutical preparations containing same
US4792555A (en) * 1987-03-20 1988-12-20 American Home Products Corporation Phospholipase A2 inhibitors
NZ234883A (en) * 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5192770A (en) 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
US5334719A (en) * 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
PL180523B1 (pl) 1994-04-01 2001-02-28 Eli Lilly & Co Nowy zwiazek, pochodna 1H-indolo-3-glioksylamidu i srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
SK77598A3 (en) 1995-12-14 1999-01-11 Merck & Co Inc Nonpeptide derivatives, pharmaceutical composition containing them and their use
CN1208412A (zh) * 1995-12-14 1999-02-17 麦克公司 促性腺激素释放激素拮抗剂
CA2309135A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors

Also Published As

Publication number Publication date
DK0675110T3 (da) 2002-10-07
RU95104885A (ru) 1997-04-27
CN1067054C (zh) 2001-06-13
CN1114310A (zh) 1996-01-03
EP1950200B1 (de) 2012-01-11
JPH07285933A (ja) 1995-10-31
PT675110E (pt) 2002-11-29
DE69527322D1 (de) 2002-08-14
PL307951A1 (en) 1995-10-02
AU688458B2 (en) 1998-03-12
NZ270848A (en) 1997-05-26
EP0675110B1 (de) 2002-07-10
EP1950200A1 (de) 2008-07-30
FI951553A0 (fi) 1995-03-31
NO951252D0 (no) 1995-03-31
US6175021B1 (en) 2001-01-16
ATE220394T1 (de) 2002-07-15
ES2179088T3 (es) 2003-01-16
DE69527322T2 (de) 2003-02-27
MX9501608A (es) 1997-02-28
ES2377223T3 (es) 2012-03-23
CA2146097A1 (en) 1995-10-02
IL113210A (en) 2001-01-28
FI951553L (fi) 1995-10-02
SI0675110T1 (en) 2002-12-31
CZ82295A3 (en) 1995-12-13
RU2128169C1 (ru) 1999-03-27
BR9501404A (pt) 1996-03-05
PE18696A1 (es) 1996-05-30
EP1081135A2 (de) 2001-03-07
TW383302B (en) 2000-03-01
NO951252L (no) 1995-10-02
US5733923A (en) 1998-03-31
AU1621795A (en) 1995-10-12
DK1950200T3 (da) 2012-04-10
CO4370099A1 (es) 1996-10-07
HU9500957D0 (en) 1995-05-29
FI114793B (fi) 2004-12-31
JP3109974B2 (ja) 2000-11-20
EP0675110A1 (de) 1995-10-04
IL113210A0 (en) 1995-06-29
EP1197484A2 (de) 2002-04-17
UA47387C2 (uk) 2002-07-15
ZA952693B (en) 1996-09-30
EP2341045A1 (de) 2011-07-06
MY112897A (en) 2001-10-31
ATE540923T1 (de) 2012-01-15
US5919810A (en) 1999-07-06
EP1081135A3 (de) 2003-11-05
PL180523B1 (pl) 2001-02-28
US6433001B1 (en) 2002-08-13
KR100368707B1 (ko) 2003-06-02
HUT72048A (en) 1996-03-28
CA2146097C (en) 2000-03-21
US5919943A (en) 1999-07-06
US5654326A (en) 1997-08-05
KR950032117A (ko) 1995-12-20

Similar Documents

Publication Publication Date Title
NO304186B1 (no) 1H-indol-3-glykosylamid og farmas°ytisk formulering
RU94012930A (ru) Новые 1-н-индол-3-ацетамиды как ингибиторы spla2 и фармацевтическая композиция на их основе
BR9401484A (pt) Hidrazida de ácido 1h-indol-3-acético e formulação farmacêutica
IL130338A0 (en) Pyrroles as sPLA2 inhibitors
KR970704695A (ko) 인돌리진 sPLA₂억제제(INDOLIZINE sPLA₂INHIBITORS)
FI941767A0 (fi) 1H-indoli-3-asetamidi sPLA2 inhibiittoreita
MX9804751A (es) Naftil acetamidas como inhibidores de la spla2.
EP1100492A4 (de) INDOLVERBINDUNGEN ALS sPLA 2? INHIBITOREN
IL130201A0 (en) Phenyl glyoxamides as spla2 inhibitors
AU5873400A (en) spla2 inhibitors
ATE247119T1 (de) Substituierte pyrroloindole
NO880405D0 (no) Fremgangsmaate til fremstilling av 3-fenyl-7h-tiazolo-/3,2-b//1,2,4/-tiazine-7-oner.
AU7053700A (en) Novel spla2 inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees